呼吸器内科学

基本情報

場所

学舎 17階

連絡先

TEL： 06-6645-3916　MAIL： gr-med-respirmed@omu.ac.jp

HP

https://www.omu.ac.jp/med/respirmed/

教育方針

学部教育

学部教育（卒前教育）では、4回生以降の臨床医学を担当しています。臓器別講義として、「呼吸器」を主宰しており、実習としては、診断学実習及び臨床実習（クリニカルクラークシップ）を担当しています。

臨床教育（研修医の育成）

卒後前期臨床研修では、呼吸器内科独自の研修経験目標を設定して、担当医として、上級医とマンツーマンで患者診療にあたります。医師として必要な基本的診療手技やプレゼンテーション能力、コミュニケーション能力の強化に加えて、特に呼吸器内科で経験が望まれる肺癌診療や呼吸不全のマネージメントなども、積極的に研修に取り入れています。
また、後期臨床研修では、医師に必要な基本的診療手技や患者対応をブラッシュアップするために主治医として研修を行っています。呼吸器内科医に必要な気管支鏡などの技術や、肺癌患者の包括的診療から呼吸不全に対する対応と人工呼吸器に至るまで、さまざまな経験を積むことができ、大学病院に特長的な治験や臨床試験にも触れることができます。さらに、専門医取得に必要な学会発表、論文執筆等の機会も設け、キャリア形成を支援しています。

研究指導

主として、後期臨床研修修了後に大学院への受け入れをおこなっています。大学院生は、教授以下教員の指導のもと実験計画、実験手技の基本から学びます。研究成果は積極的にアメリカ、ヨーロッパ等の国際学会で発表しています。
大学院修了後も研究分野での研鑽を積まれる場合、海外での研究留学も勧奨しています。これまで、当科から欧米の施設への留学実績があり、具体的には、ピッツバーグ大学（米国）、カリフォルニア大学デイビス校（米国）、シャーブルック大学（カナダ）、マギル大学（カナダ）、ベス・イスラエル医療センター（米国）などの施設を紹介させていただくことも可能です。

研究について

当科は臨床医学の教室であり、臨床からかけ離れた「研究のための研究」ではなく、臨床に還元可能な「患者のための研究」を旨としています。臨床上の未解決な問題を解決したい、未解明な病因・病態を解明したいという探究心から研究は始まります。よって、動物モデルだけではなく、臨床研究や臨床検体を用いた研究も重視しており、気管支鏡検査、肺機能検査、心肺運動負荷検査などの臨床検査や患者の診療にあたりながら研究をすすめています。

教室の最新の業績

1. The usefulness of full-thickness biopsy during semi-rigid pleuroscopy for differentiating between malignant pleural mesothelioma and non-specific pleurisy
   Ueda T, Nakai T, Tanaka S, Nagamine H, Miyamoto A, Nishimura M, Matsumoto Y, Sato K, Yamada K, Watanabe T, Asai K, Matsumoto Y, Mikami Y, Kawaguchi T
   BMC Pulm Med. 2025 Dec 10;25(1):553. doi: 10.1186/s12890-025-03982-6.PMID: 41366665
2. Association between pleurodesis before immunotherapy and pneumonitis in non-small cell lung cancer
   Mizutani M, Ihara Y, Sawa K, Sugimoto A, Nagamine H, Matsumoto Y, Tani Y, Oka Y, Kaneda H, Bito T, Kawaguchi T, Shintani A
   Respir Investig. 2025 Nov;63(6):1194-1200. doi: 10.1016/j.resinv.2025.09.016. Epub 2025 Sep 25.PMID: 41004952
3. Real-World Safety and Effectiveness of Fluticasone Furoate/Umeclidinium/Vilanterol in Patients with Asthma: Final Analysis of a Post-Marketing Surveillance in Japan
   Asai K, Morioka Y, Ito R, Komatsubara M, Maruoka H
   Adv Ther. 2026 Jan;43(1):317-332. doi: 10.1007/s12325-025-03421-2. Epub 2025 Nov 28.PMID: 41313548
4. Prevalence of dysfunctional breathing in the Japanese community and the involvement of tobacco use status: The JASTIS study 2024
   Hirai K, Yamada K, Asai K, Tsutsumi M, Ueda T, Toyokura E, Furukawa Y, Miyamoto A, Nishimura M, Sato K, Watanabe T, Maruoka S, Gon Y, Tabuchi T, Kawaguchi T.
   Respir Investig. 2025 Nov;63(6):1377-1382. doi: 10.1016/j.resinv.2025.10.002. Epub 2025 Nov 12.PMID: 41260862
5. Dual use of combustible and heated tobacco products associates persistent symptoms with a history of COVID-19: a JASTIS 2023 cross‑sectional study
   Toyokura E, Yamada K, Asai K, Tsutsumi M, Ueda T, Hirai K, Furukawa Y, Miyamoto A, Nishimura M, Sato K, Watanabe T, Tabuchi T, Kawaguchi T
   Sci Rep. 2025 Nov 14;15(1):38659. doi: 10.1038/s41598-025-22050-x.PMID: 41238605
6. Differences in Lung Cancer-related Clinical Practice and Basic Research Background between Japan and China: A Narrative Review
   Wang L, Miao Y, Gu Y, Kawaguchi T, Mizutani M, Nakai T, Watanabe T, Asai K, Zhang H, Cai W,  Tani Y, Kaneda H
   Intern Med. 2025 Sep 1;64(17):2524-2533. doi: 10.2169/internalmedicine.4808-24. Epub 2025 Mar 1.PMID: 41238605
7. Impact of physical activity on respiratory disease: Current status and therapeutic implications
   Asai K
   Respir Investig. 2025 Nov;63(6):1187-1193. doi: 10.1016/j.resinv.2025.09.020. Epub 2025 Sep 25.PMID: 41004951
8. Application of endobronchial ultrasound-guided cryobiopsy for centrally located intrapulmonary lesions: A retrospective cohort study
   Nakai T, Tanaka S, Nagamine H, Miyamoto A, Nishimura M, Matsumoto Y, Sato K, Yamada K, Watanabe T, Asai K, Matsumoto Y, Mikami Y, Kawaguchi T
   Lung Cancer. 2025 Jul:205:108636. doi: 10.1016/j.lungcan.2025.108636. Epub 2025 Jun 24.PMID: 40570408
9. Relationship Between T790M Allele Frequency and Therapeutic Effects Before and After EGFR-TKI Administration Using Droplet Digital PCR in Non-small-cell Lung Cancer With EGFR Mutation
   Ogawa K, Kaneda H, Koh Y, Matsumoto Y, Sawa K, Tamiya M, Ishikawa N, Minami K, Suzuki H, Eguchi Y, Kanazu M, Sato Y, Kawaguchi T.
   Cancer Diagn Progn. 2025 May 3;5(3):285-299. doi: 10.21873/cdp.10441. eCollection 2025 May-Jun.PMID: 40322218
10. Long-term, real-world effectiveness of biologics for severe uncontrolled asthma: The PROSPECT study
    Asai K, Iwanaga T, Takahashi M, Eda M, Hirai T, Yabuta T, Makita N, Tohda Y
    Respir Investig. 2025 May;63(3):444-452. doi: 10.1016/j.resinv.2025.03.007. Epub 2025 Apr 4.PMID: 40186961
11. Respiratory Muscle Strength as a Predictor of Exacerbations in Patients with Chronic Obstructive Pulmonary Disease
    Furukawa Y, Miyamoto A, Asai K, Tsutsumi M, Hirai K, Ueda T, Toyokura E, Nishimura M, Sato K, Yamada K, Watanabe T, Kawaguchi T
    Respirology. 2025 May;30(5):408-416. doi: 10.1111/resp.70003. Epub 2025 Feb 26.PMID: 40009650
12. Efficacy of ramucirumab combined with erlotinib or osimertinib in untreated EGFR-mutated NSCLC patients with asymptomatic brain metastases: insights from molecular biomarkers in the RELAY-brain trial
    Kaneda H, Daga H, Okada A, Nakatani Y, Tani Y, Oka T, Sawa K, Sakai K, Nishio K, Kawaguchi T
    Invest New Drugs. 2025 Feb;43(1):147-156. doi: 10.1007/s10637-025-01505-y. Epub 2025 Jan 23.PMID: 39847172
13. Establishing a new human lung squamous cell carcinoma cell line, OMUL-1, expressing insulin-like growth factor 1 receptor and programmed cell death ligand 1
    Nagamine H, Yashiro M, Mizutani M, Sugimoto A, Matsumoto Y, Tani Y, Kaneda H, Yamada K, Watanabe T, Asai K, Suzuki S, Kawaguchi T
    Thorac Cancer. 2025 Jan;16(1):e15488. doi: 10.1111/1759-7714.15488. Epub 2024 Nov 17.PMID: 39552203
14. Application and Advancement of Bronchoscopic Biopsy Techniques for the Diagnosis of Pulmonary Nodules
    Wang L, Miao Y, Kaneda H, Kawaguchi T, Sheng Y, Gu Y, Mizutani M, Watanabe T, Asai K, Zhang H, Tani Y, Nakai T
    Respiratory Endoscopy.November 2024;2(3):122-127
15. Insulin-like growth factor 1 receptor expression correlates with programmed death ligand 1 expression and poor survival in non-small cell lung cancer.
    Nagamine H, Yashiro M, Mizutani M, Sugimoto A, Matsumoto Y, Tani Y, Sawa K,Kaneda H, Yamada K, Watanabe T, Asai K, Suzuki S, Kawaguchi T
    PLoS One. 2024 Oct 4;19(10):e0297397. doi: 10.1371/journal.pone.0297397. eCollection 2024.PMID: 39365756
16. Randomized controlled trial to examine the tolerability of bronchoscopy with and without pharyngeal laryngeal anesthesia (TACOYAKI study)
    Ueda T, Tanaka H, Ueno K, Kobayashi M, Kadotani H, Uenishi R, Ishii M, Takeda N, Matsushita H, Kawaguchi T
    Randomized Controlled Trial Respir Investig. 2024 Sep;62(5):867-871. doi: 10.1016/j.resinv.2024.07.007. Epub 2024 Jul 27.PMID: 39068896
17. Derived neutrophil-to-lymphocyte ratio has the potential to predict safety and outcomes of durvalumab after chemoradiation in non-small cell lung cancer
    Sugimoto A, Kaneda H, Yoshimoto N, Nagata K, Fujii T, Michimoto K, Ueno S, Kamimori T, Ishii Y, Sakagami M, Inokuchi H, Shibuya K, Mizutani M, Nagamine H, Nakahama K, Matsumoto Y, Tani Y, Sawa K, Kawaguchi T
    Sci Rep. 2024 Aug 23;14(1):19596. doi: 10.1038/s41598-024-70214-y.PMID: 39179598
18. Compartmentalized mitochondrial ferroptosis converges with optineurin-mediated mitophagy to impact airway epithelial cell phenotypes and asthma outcomes.
    Yamada K, St Croix C, Stolz DB, Tyurina YY, Tyurin VA, Bradley LR, Kapralov AA, Deng Y, Zhou X, Wei Q, Liao B, Fukuda N, Sullivan M, Trudeau J, Ray A, Kagan VE, Zhao J, Wenzel SE
    Nat Commun. 2024 Jul 10;15(1):5818. doi: 10.1038/s41467-024-50222-2.PMID: 38987265
19. Lack of Association Between Immunotherapy and Improvement of Survival for Non-small Cell Lung Cancer Patients With Hemodialysis: A Nationwide Retrospective Cohort Study
    Sawa K, Ihara Y, Imai T, Sugimoto A, Nagamine H, Ogawa K, Nakahama K, Matsumoto Y, Tani Y, Kaneda H, Mitsuoka S, Kawaguchi T, Shintani A.
    Clin Lung Cancer. 2024 Mar;25(2):144-150.e3. doi: 10.1016/j.cllc.2023.11.003. Epub 2023 Nov 7.PMID: 38042690
20. Comparison of the specimen quality of endobronchial ultrasound-guided intranodal forceps biopsy using standard-sized forceps versus mini forceps for lung cancer: A prospective study
    Nakai T, Matsumoto Y, Ueda T, Kuwae Y, Tanaka S, Miyamoto A, Matsumoto Y, Sawa K, Sato K, Yamada K, Watanabe T, Asai K, Furuse H, Uchimura K, Imabayashi T, Uenishi R, Fukui M, Tanaka H, Ohsawa M, Kawaguchi T, Tsuchida T.
    Respirology. 2024 May;29(5):396-404. doi: 10.1111/resp.14659. Epub 2024 Jan 21.PMID: 38246887
21. Clinical significance of KL-6 in immune-checkpoint inhibitor treatment for non-small cell lung cancer
    Nakahama K, Izumi M, Yoshimoto N, Fukui M, Sugimoto A, Nagamine H, Ogawa K, Sawa K, Tani Y, Kaneda H, Mitsuoka S, Watanabe T, Asai K, Kawaguchi T.
    Cancer Chemother Pharmacol. 2023 Nov;92(5):381-390. doi: 10.1007/s00280-023-04573-0. Epub 2023 Aug 22.PMID: 37606723
22. RBM17 Expression Is Associated With the Efficacy of ICI Monotherapy in NSCLC With Low PD-L1 Expression
    Nagamine H, Yashiro M, Yoshimoto N, Izumi M, Sugimoto A, Nakahama K, Ogawa K, Matsumoto Y, Sawa K, Tani Y, Kaneda H, Mitsuoka S, Yamada K, Watanabe T, Aasai K, Fukumura K, Mayeda A, Kawaguchi T.
    Anticancer Res. 2023 Oct;43(10):4663-4672. doi: 10.21873/anticanres.16662.PMID: 37772582
23. Diagnostic Utility and Safety of Non-Intubated Cryobiopsy Technique Using a Novel Ultrathin Cryoprobe in Addition to Conventional Biopsy Techniques for Peripheral Pulmonary Lesions
    Nakai T, Watanabe T, Kaimi Y, Shiomi K, Ando K, Miyamoto A, Ogawa K, Matsumoto Y, Sawa K, Sato K, Asai K, Matsumoto Y, Mikami Y, Ohsawa M, Kawaguchi T.
    Respiration. 2023;102(7):503-514. doi: 10.1159/000531010. Epub 2023 Jun 28.PMID: 37379810
24. Influence of Smoking History on the Effectiveness of Immune-checkpoint Inhibitor Therapy for Non-small Cell Lung Cancer: Analysis of Real-world Data
    Nakahama K, Izumi M, Yoshimoto N, Fukui M, Sugimoto A, Nagamine H, Ogawa K, Sawa K, Tani Y, Kaneda H, Mitsuoka S, Watanabe T, Asai K, Kawaguchi T.
    Anticancer Res. 2023 May;43(5):2185-2197. doi: 10.21873/anticanres.16381.PMID: 37097681
25. Distinct contributions of muscle mass and strength stratified by nutritional status to physical activity in patients with chronic obstructive pulmonary disease
    Kawai T, Asai K, Miyamoto A, Yamada K, Furukawa Y, Toyokura E, Nishimura M, Sato K, Watanabe T, Kawaguchi T.
    Respir Investig. 2023 Jul;61(4):389-397. doi: 10.1016/j.resinv.2023.03.001. Epub 2023 Apr 21.PMID: 37088061
26. A Large-Scale Prospective Concordance Study of Plasma- and Tissue-Based Next-Generation Targeted Sequencing for Advanced Non-Small Cell Lung Cancer (LC-SCRUM-Liquid)
    Sugimoto A, Matsumoto S, Udagawa H, Itotani R, Usui Y, Umemura S, Nishino K, Nakachi I, Kuyama S, Daga H, Hara S, Miyamoto S, Kato T, Sakakibara-Konishi J, Tabata E, Nakagawa T, Kawaguchi T, Sakai T, Shibata Y, Izumi H, Nosaki K, Zenke Y, Yoh K, Goto K.
    Clin Cancer Res. 2023 Apr 14;29(8):1506-1514. doi: 10.1158/1078-0432.CCR-22-1749.PMID: 36201167
27. Vimentin expression correlates with immune checkpoint inhibitor efficacy in non-small cell lung cancer
    Nakahama K, Izumi M, Yoshimoto N, Fukui M, Sugimoto A, Nagamine H, Ogawa K, Sawa K, Tani Y, Kaneda H, Mitsuoka S, Watanabe T, Asai K, Kawaguchi T.
    Cancer. 2023 Aug 1;129(15):2297-2307. doi: 10.1002/cncr.34782. Epub 2023 Apr 6.PMID: 37021822
28. Diagnostic efficacy of cryobiopsy for peripheral pulmonary lesions: A propensity score analysis
    Furuse H, Matsumoto Y, Nakai T, Tanaka M, Nishimatsu K, Uchimura K, Imabayashi T, Tsuchida T, Ohe Y.
    Lung Cancer. 2023 Apr:178:220-228. doi: 10.1016/j.lungcan.2023.02.022. Epub 2023 Mar 1.PMID: 36893563
29. 29.Ethnic differences in lung cancer: "we can differ and still unite around common goals."
    Kawaguchi T.
    Respir Investig. 2023 May;61(3):355-356. doi: 10.1016/j.resinv.2023.02.002. Epub 2023 Mar 22.PMID: 36963275
30. The Impact of Estrogen Receptor Expression on Mutational Status in the Evolution of Non-Small Cell Lung Cancer
    Tani Y, Kaneda H, Koh Y, Tamiya A, Isa S, Kubo A, Ogawa K, Matsumoto Y, Sawa K, Yoshimoto N, Mitsuoka S, Kawaguchi T.
    Clin Lung Cancer. 2023 Mar;24(2):165-174. doi: 10.1016/j.cllc.2022.12.010. Epub 2022 Dec 31.PMID: 36646585
31. Rifampicin exerts anti-mucoviscous activity against hypervirulent Klebsiella pneumoniae via binding to the RNA polymerase β subunit
    Tohda M, Oinuma KI, Sakiyama A, Tsubouchi T, Niki M, Namikawa H, Yamane K, Yamada K, Watanabe T, Asai K, Kakeya H, Kaneko Y, Kawaguchi T.
    J Glob Antimicrob Resist. 2023 Mar:32:21-28. doi: 10.1016/j.jgar.2022.11.018. Epub 2022 Dec 23.PMID: 36572148
32. COVID-19 vaccination benefits in preventing severe disease in mild-to-moderate cases: An analysis in the first specialized hospital for COVID-19 in Japan
    Kobayashi M, Miyamoto A, Watanabe T, Sawa K, Sato K, Yamada K, Yoshii N, Yamada K, Kawamoto K, Uji M, Shiraishi S, Asai K, Kakeya H, Kawaguchi T.
    Respir Investig. 2023 Mar;61(2):230-239. doi: 10.1016/j.resinv.2022.12.011. Epub 2023 Feb 2.PMID: 36774816
33. A Culture Supernatant from an Actinomycete sp. Affects Biofilm Formation and Virulence Expression of Candida auris
    Yamane K, Niki M, Tsubouchi T, Watanabe T, Asai K, Oinuma KI, Sakiyama A, Saren C, Matsumoto Y, Makimura K, Kaneko Y, Kawaguchi T.
    Med Mycol J. 2023;64(1):7-17. doi: 10.3314/mmj.22-00026.PMID: 36858631
34. Association of combustible cigarettes and heated tobacco products use with SARS-CoV-2 infection and severe COVID-19 in Japan: a JASTIS 2022 cross-sectional study
    Nishimura M, Asai K, Tabuchi T, Toyokura E, Kawai T, Miyamoto A, Watanabe T, Kawaguchi T.
    Sci Rep. 2023 Feb 2;13(1):1120. doi: 10.1038/s41598-023-28006-3.PMID: 36732559
35. SP142 evaluation contributes to the prediction of immune checkpoint inhibitor efficacy in non-small cell lung cancer with high PD-L1 expression assessed by 22C3
    Nakahama K, Osawa M, Izumi M, Yoshimoto N, Sugimoto A, Nagamine H, Ogawa K, Matsumoto Y, Sawa K, Tani Y, Kaneda H, Mitsuoka S, Watanabe T, Asai K, Kawaguchi T.
    Transl Lung Cancer Res. 2022 Dec;11(12):2438-2451. doi: 10.21037/tlcr-22-496.PMID: 36636414
36. Vascular endothelial growth factor receptor 2 expression and immunotherapy efficacy in non-small cell lung cancer
    Nakahama K, Kaneda H, Osawa M, Fukui M, Izumi M, Yoshimoto N, Sugimoto A, Nagamine H, Ogawa K, Matsumoto Y, Sawa K, Tani Y, Mitsuoka S, Watanabe T, Asai K, Kawaguchi T.
    Cancer Sci. 2022 Sep;113(9):3148-3160. doi: 10.1111/cas.15464. Epub 2022 Jul 18.PMID: 35722982
37. Association of thyroid transcription factor-1 with the efficacy of immune-checkpoint inhibitors in patients with advanced lung adenocarcinoma
    Nakahama K, Kaneda H, Osawa M, Izumi M, Yoshimoto N, Sugimoto A, Nagamine H, Ogawa K, Matsumoto Y, Sawa K, Tani Y, Mitsuoka S, Watanabe T, Asai K, Kawaguchi T.
    Thorac Cancer. 2022 Aug;13(16):2309-2317. doi: 10.1111/1759-7714.14560. Epub 2022 Jul 8.PMID: 35808895
38. Prognostic impact of pretreatment T790M mutation on outcomes for patients with resected, EGFR-mutated, non-small cell lung cancer
    Matsumoto Y, Kawaguchi T, Watanabe M, Isa SI, Ando M, Tamiya A, Kubo A, Kitagawa C, Yoshimoto N, Koh Y.
    BMC Cancer. 2022 Jul 15;22(1):775. doi: 10.1186/s12885-022-09869-7.PMID: 35840951
39. Vascular endothelial growth factor receptor 2 expression and immunotherapy efficacy in non-small cell lung cancer
    Nakahama K, Kaneda H, Osawa M, Fukui M, Izumi M, Yoshimoto N, Sugimoto A, Nagamine H, Ogawa K, Matsumoto Y, Sawa K, Tani Y, Mitsuoka S, Watanabe T, Asai K, Kawaguchi T
    Cancer Sci. 2022 Sep;113(9):3148-3160. doi: 10.1111/cas.15464. Epub 2022 Jul 18.PMID: 35722982
40. Safety profile and risk factors for bleeding in transbronchial cryobiopsy using a two-scope technique for peripheral pulmonary lesions
    Nakai T, Watanabe T, Kaimi Y, Ogawa K, Matsumoto Y, Sawa K, Okamoto A, Sato K, Asai K, Matsumoto Y, Ohsawa M, Kawaguchi T
    BMC Pulm Med. 2022 Jan 10;22(1):20. doi: 10.1186/s12890-021-01817-8.PMID: 35000601

主な研究内容

現在の主な研究テーマ

閉塞性肺疾患気道炎症の機序解明

細胞実験、動物実験、さらには閉塞性肺疾患患者さんから採取した喀痰、気管支鏡検体から気道炎症を評価し、気管支喘息、慢性閉塞性肺疾患等の閉塞性肺疾患の病態解明を目指しています。

肺がんに対する新規化学療法レジメの開発

抗がん剤治療が主体となる進行非小細胞肺がんに対する新規治療レジメの開発を目指し、臨床試験を行っています。また、切除肺がん標本など臨床検体から分子生物学を駆使して遺伝子変異スクリーニングを行い、治療反応性などとの関連を検討し、がん病態の解明を目指しています。

臨床への取り組み

呼吸器疾患は、一刻を争う急性呼吸不全などのエマージェンシー状態から、呼吸ケアやリハビリテーションを施行する慢性期まで扱います。また、肺がん等の腫瘍性病変も対象になります。疾患範囲の広い診療科です。当科は、日本呼吸器学会、日本アレルギー学会、日本呼吸器内視鏡学会などの呼吸器関連学会の認定施設であり、また、総合内科専門医、内科指導医、がん薬物療法専門医を多数擁して、幅広い呼吸器疾患の診断・治療に対応しています。
患者さんのQOL（Quality of Life; 生活の質）の改善を目指し、「大阪呼吸器疾患診療ネットワーク」を市中臨床医家の先生方と組織し、病診連携を推進しております。

スタッフ

参考写真